NCT04914377View on ClinicalTrials.gov

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

December 16, 2021

Study Completion Date

January 1, 2022

Conditions
Covid19
Interventions
DRUG

TQ Formula/Tab

TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).

Trial Locations (3)

33018

L & A Morales Healthcare, Hialeah

77054

United Memorial Medical Center, Houston

92108

Respire Research, San Diego

Sponsors
All Listed Sponsors
lead

Novatek Pharmaceuticals

INDUSTRY

NCT04914377 - To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants | Biotech Hunter | Biotech Hunter